Bioengineered Therapies for Kidney Disease

Trestle Biotherapeutics is focused on developing innovative bioengineered therapies aimed at addressing kidney disease, particularly for patients suffering from end-stage renal disease (ESRD). The company is pioneering the creation of implantable therapeutic tissues that can potentially replace the need for dialysis and delay the necessity for kidney transplants. This approach leverages advanced technologies in stem cell biology, biofabrication, fluidics, and cell manufacturing, with the goal of creating functional tissues that can restore kidney function and improve the quality of life for millions of patients worldwide.

The team at Trestle Biotherapeutics is composed of experts in various fields, including vascular biology, tissue engineering, and regenerative medicine. Their combined experience in developing complex 3D human tissue systems and bioprinting techniques positions them to tackle the challenges associated with kidney disease treatment. By bridging scientific disciplines and fostering collaboration among global experts, Trestle aims to create novel solutions that could transform the landscape of organ failure therapies, ultimately benefiting a vast population of patients who currently have limited treatment options.

United States

Trestle Biotherapeutics, Inc. is a preclinical stage company developing bioengineered therapies for patients living with end stage renal disease. Once implanted, these bioengineered stem cell-derived tissues will get patients off dialysis, delay their need for transplantation, and one day become replacement organs.

Trestle Biotherapeutics

Company Details